Rchr
J-GLOBAL ID：201901011071873398   Update date: Jun. 04, 2024

Isono Makoto

Isono Makoto
Affiliation and department：
Tokorozawa Isono Clinic

About Tokorozawa Isono Clinic


Research field  (1)： Urology
Research theme for competitive and other funds  (2)：
  • 2019 - 2022 DNA修復経路に着目した、シスプラチン耐性の膀胱癌に対する新たな治療法の開発
  • 2014 - 2015 進行腎癌に対する新規治療の開発
Papers (41)：
  • Shuhei Yamada, Haruka Miyata, Makoto Isono, Kanta Hori, Junko Yanagawa, Aiko Murai, Tomoyuki Minowa, Yuka Mizue, Kenta Sasaki, Kenji Murata, et al. Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma. Cancer immunology, immunotherapy : CII. 2023. 72. 7. 2057-2065
  • Makoto Isono, Kazuki Okubo, Takako Asano, Akinori Sato. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells. PloS one. 2022. 17. 4. e0266476
  • Kazuki Okubo, Makoto Isono, Takako Asano, Nina REßING, Wolfgang A Schulz, Finn K Hansen, Akinori Sato. Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells. Anticancer research. 2021. 41. 6. 2901-2912
  • Makoto Isono, Kazuki Okubo, Takako Asano, Akinori Sato. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells. Scientific reports. 2021. 11. 1. 10181-10181
  • Kazuki Okubo, Fumiko Hamabe, Kosuke Miyai, Makoto Isono, Hiroshi Shinmoto, Akinori Sato. Prostate cancer recurrence mimicking invasive urothelial cancer of the bladder. Urology case reports. 2020. 33. 101421-101421
ｍore...
MISC (18)：
  • 升永 綾子, 伊藤 敬一, 川口 真, 新地 祐介, 磯野 誠, 田崎 新資, 黒田 健司, 佐藤 全伯, 朝隈 純一, 堀口 明男, et al. 進行性腎癌に対するアキシチニブの治療成績. 泌尿器外科. 2018. 31. 臨増. 856-856
  • Asano Takako, Sato Akinori, Okubo Kazuki, Isono Makoto, Asano Tomohiko. RITONAVIR AND IXAZOMIB INHIBIT RENAL CANCER GROWTH IN VITRO AND IN VIVO BY INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY. JOURNAL OF UROLOGY. 2018. 199. 4. E955
  • Isono Makoto, Sato Akinori, Asano Takako, Okubo Kazuki, Asano Tomohiko. Sensitization of Urothelial Carcinoma Cells to Gemcitabine by the Checkpoint Kinase Inhibitor MK-8776. CANCER SCIENCE. 2018. 109. 305
  • Sato Akinori, Asano Takako, Isono Makoto, Okubo Kazuki, Asano Tomohiko. Inducing endoplasmic reticulum stress to kill urological cancer cells. CANCER SCIENCE. 2018. 109. 356
  • Asano Takako, Sato Akinori, Okubo Kazuki, Isono Makoto, Asano Tomohiko. Ritonavir interacts with ixazomib to inhibit renal cancer growth synergistically. CANCER SCIENCE. 2018. 109. 332
ｍore...
Lectures and oral presentations  (95)：
  • The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in long-term cisplatin treated bladder cancer cells.
    (The 34th Annual Congress of European Association of Urology 2019)
  • 進行性腎癌に対するアキシチニブの治療成績
    (泌尿器外科 2018)
  • The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 sensitizes bladder cancer cells to gemcitabine.
    (The 33rd Annual Congress of European Association of Urology 2018)
  • 急速な転機を辿った腎粘液管状紡錘細胞癌の1例
    (日本泌尿器科学会東部総会プログラム・抄録集 2018)
  • Inducing endoplasmic reticulum stress to kill urological cancer cells
    (CANCER SCIENCE 2018)
ｍore...
Professional career (1)：
  • 博士(医学) (防衛医科大学校)
Work history (11)：
  • 2023 - 現在 Tokorozawa Isono Clinic
  • 2021 - 2023 我孫子東邦病院 泌尿器科
  • 2019 - 2021 恵佑会札幌病院 泌尿器科
  • 2018 - 2021 Sapporo Medical University
  • 2017 - 2019 陸上自衛隊第11旅団司令部 医務官室 医務官
Show all
Association Membership(s) (5)：
JAPAN SOCIETY FOR REPRODUCTIVE MEDICINE ,  Japanese Society for Dialysis Therapy ,  THE JAPANESE CANCER ASSOCIATION ,  JAPANESE SOCIETY OF ENDOUROLOGY ,  THE JAPANESE UROLOGICAL ASSOCIATION
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM